trial · primary record
Pembrolizumab
Esophageal Squamous Cell Carcinoma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 298 |
| Primary completion | 2032-01-04 |
| Primary endpoint | Percentage of Participants who Experience Dose Limiting Toxicities (DLTs) During the Safety Lead-In Phase |
| Registry ID | NCT06780111 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:32.842Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06780111
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.